Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, zoletil®: Difference between acute and repeated exposure

Behavioural Brain Research

Volumn 233, Issue 2, 2012, Pages 434-442

  de la Peña, June Bryan I ^a   Lee, Hae Chang ^a   de la Peña, Ike C ^a   Woo, Tae Soon ^a   Yoon, Seo Young ^a   Lee, Hye Lim ^a   Han, Jin Soo ^b   Lee, Jeong Ik ^b   Cho, Yoon Ju ^c   Shin, Chan Young ^b   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Konkuk University   (South Korea)

^c Seojeong College University   (South Korea)

Author keywords

Abuse; Place conditioning; Self administration; Tiletamine; Zolazepam; Zoletil

Indexed keywords

KETAMINE; TILETAMINE; TILETAMINE PLUS ZOLAZEPAM; ZOLAZEPAM;

ACUTE EXPOSURE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG REEXPOSURE; DRUG SELF ADMINISTRATION; EXPOSURE; MALE; NERVE FUNCTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANESTHETICS; ANIMALS; ANTI-ANXIETY AGENTS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; KETAMINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); REWARD; SELF ADMINISTRATION; TILETAMINE; TIME FACTORS; ZOLAZEPAM;

EID: 84862495073     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.05.038     Document Type: Article

References (43)

1. April 5, 2012. http://www.virbac.cz/zoletil_guide_cats.html.
2. Ferrari L., Turrini G., Rostello C., Guidi A., Casartelli A., Piaia A., et al. Evaluation of two combinations of Domitor, Zoletil 100, and Euthatal to obtain long-term nonrecovery anesthesia in Sprague-Dawley rats. Comparative Medicine 2005, 55:256-264.
3. April 5, 2012. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm%3Ffr=1308.13.
4. Saha D.C., Saha A.C., Malik G., Astiz M.E., Rackow E.C. Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats. Journal of the American Association for Laboratory Animal Science: JAALAS 2007, 46:74-80.
5. Guarda I.F., Saad W.A., de Arruda Camargo L.A. Nitric oxide and angiotensin II receptors mediate the pressor effect of angiotensin II: a study in conscious and zoletil-anesthetized rats. Anesthesia and Analgesia 2007, 105:1293-1297. table of contents.
6. Walzer C., Huber C. Partial antagonism of tiletamine-zolazepam anesthesia in cheetah. Journal of Wildlife Diseases 2002, 38:468-472.
7. Lee C.C., Lin Y.Y., Hsu C.W., Chu S.J., Tsai S.H. Movement disorder caused by abuse of veterinary anesthesia containing tiletamine. American Journal of Emergency Medicine 2009, 27:e5-e6. 1022.
8. Chung H., Choi H., Kim E., Jin W., Lee H., Yoo Y. A fatality due to injection of tiletamine and zolazepam. Journal of Analytical Toxicology 2000, 24:305-308.
9. Cording C.J., DeLuca R., Camporese T., Spratt E. A fatality related to the veterinary anesthetic telazol. Journal of Analytical Toxicology 1999, 23:552-555.
10. ®, a veterinary anaesthetic, by a 16 year-old male. Clinical Intensive Care 2002, 13:139-142.
11. Quail M.T., Weimersheimer P., Woolf A.D., Magnani B. Abuse of telazol: an animal tranquilizer. Journal of Toxicology - Clinical Toxicology 2001, 39:399-402.
12. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence 2003, 70:S55-S72.
13. Shippenberg T.S., Koob G.F. Recent advances in animal models of drug addiction. Neuropsychopharmacology: the fifth generation of progress 2002, 1381-1397. American College of Neuropsychopharmacology. L. Kenneth, D.C. Davis, J.T. Coyle, C. Nemeroff (Eds.).
14. van der Kam E.L., De Vry J., Tzschentke T.M. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. European Journal of Pharmacology 2009, 606:94-101.
15. Gray A., Allison C., Pratt J.A. A role for AMPA/kainate receptors in conditioned place preference induced by diazepam in the rat. Neuroscience Letters 1999, 268:127-130.
16. Xu D.D., Mo Z.X., Yung K.K., Yang Y., Leung A.W. Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neuro-signals 2006, 15:322-331.
17. De Luca M.T., Badiani A. Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology (Berlin) 2011, 214:549-556.
18. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology (Berlin) 1997, 134:1-37.
19. van der Kam E.L., de Vry J., Tzschentke T.M. Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat. Behavioural Pharmacology 2007, 18:717-724.
20. dela Pena I.C., Ahn H.S., Choi J.Y., Shin C.Y., Ryu J.H., Cheong J.H. Methylphenidate self-administration and conditioned place preference in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Behavioural Pharmacology 2011, 22:31-39.
21. Winger G., Hursh S.R., Casey K.L., Woods J.H. Relative reinforcing strength of three N-methyl-d-aspartate antagonists with different onsets of action. Journal of Pharmacology and Experimental Therapeutics 2002, 301:690-697.
22. Marcus M.M., Mathe J.M., Nomikos G.G., Svensson T.H. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology 2001, 40:482-490.
23. Noda Y., Miyamoto Y., Mamiya T., Kamei H., Furukawa H., Nabeshima T. Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. Journal of Pharmacology and Experimental Therapeutics 1998, 286:44-51.
24. dela Peña I.C., Ahn H.S., Shin C.Y., Cheong J.H. Neuroadaptations involved in long-term exposure to ADHD pharmacotherapies: alterations that support dependence liability of these medications?. Biomolecules and Therapeutics 2011, 19:19-20.
25. Smith R.C., Meltzer H.Y., Arora R.C., Davis J.M. Effects of phencyclidine on [3H] catecholamine and [3H] serotonin uptake in synaptosomal preparations from rat brain. Biochemical Pharmacology 1977, 26:1435-1439.
26. Del Arco A., Segovia G., Mora F. Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity. Psychopharmacology (Berlin) 2008, 201:325-338.
27. Nomikos G.G., Spyraki C. Effects of ritanserin on the rewarding properties of d-amphetamine, morphine and diazepam revealed by conditioned place preference in rats. Pharmacology Biochemistry and Behavior 1988, 30:853-858.
28. Spyraki C., Fibiger H.C. A role for the mesolimbic dopamine system in the reinforcing properties of diazepam. Psychopharmacology (Berlin) 1988, 94:133-137.
29. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology (Berlin) 2000, 153:31-43.
30. Licata S.C., Rowlett J.K. Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacology Biochemistry and Behavior 2008, 90:74-89.
31. Prus A.J., James J.R., Rosecrans J.A. Conditioned place preference. Methods of behavior analysis in neuroscience 2009, CRC Press, Boca Raton, FL. J.J. Buccafusco (Ed.).
32. Tsuda M., Suzuki T., Misawa M. NMDA receptor antagonists potently suppress the spontaneous withdrawal signs induced by discontinuation of long-term diazepam treatment in Fischer 344 rats. Brain Research 1998, 790:82-90.
33. Fahey J.M., Pritchard G.A., Pratt J.S., Shader R.I., Greenblatt D.J. Lorazepam attenuates the behavioral effects of dizocilpine. Pharmacology Biochemistry and Behavior 1999, 62:103-110.
34. Koff J.M., Pritchard G.A., Greenblatt D.J., Miller L.G. The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology 1997, 55:217-227.
35. Souza-Pinto L.F., Castilho V.M., Brandao M.L., Nobre M.J. The blockade of AMPA-kainate and NMDA receptors in the dorsal periaqueductal gray reduces the effects of diazepam withdrawal in rats. Pharmacology Biochemistry and Behavior 2007, 87:250-257.
36. Kitaichi K., Noda Y., Hasegawa T., Furukawa H., Nabeshima T. Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats. European Journal of Pharmacology 1996, 318:7-9.
37. Nabeshima T., Kitaichi K., Noda Y. Functional changes in neuronal systems induced by phencyclidine administration. Annals of the New York Academy of Sciences 1996, 801:29-38.
38. Noda Y., Nabeshima T. Involvement of signal transduction cascade via dopamine-D1 receptors in phencyclidine dependence. Annals of the New York Academy of Sciences 2004, 1025:62-68.
39. Narendran R., Frankle W.G., Keefe R., Gil R., Martinez D., Slifstein M., et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. American Journal of Psychiatry 2005, 162:2352-2359.
40. Mora F., Segovia G., Del Arco A. Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Research Reviews 2008, 58:340-353.
41. Keilhoff G., Becker A., Grecksch G., Wolf G., Bernstein H.G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 2004, 126:591-598.
42. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 2007, 27:11496-11500.
43. Tan K.R., Rudolph U., Luscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends in Neurosciences 2011, 34:188-197.